Ro advertises a weight-management program with clinician access and a separate medication charge. That separation is the most useful place to begin this review. A membership price can describe the care service without including the medicine that may be prescribed.
We checked Ro’s official program and pricing pages on September 23, 2026. This article explains the public offer and questions to confirm; it does not report patient enrollment, independent clinician testing, or a promise that insurance will approve a prescription.
One thing to keep with you
Add the membership and medication costs, and check whether a low monthly equivalent requires a prepaid commitment.
What the membership is meant to provide
Ro’s public pages describe an assessment process, an individualized plan when appropriate, provider messaging, check-ins, and insurance support. The pricing page explicitly states that medication cost is not included in the membership fee. Access to a prescribing process also does not mean every applicant receives a prescription.
Ask what is included for your actual plan, whether additional assessment or testing is needed, and how the clinician evaluates the product choice. Our semaglutide overview is a useful starting point for bringing your health history and goals to that conversation without assuming a medicine is already selected.
Checked with: Ro: current program pricing · Ro: weight-management program · NIDDK: prescription weight-management medicines
The membership figures currently advertised
The checked pricing page lists $39 for the first month and $149 for an ongoing monthly plan. It also lists lower monthly equivalents for prepaid commitments: $99 for a three-month term, $89 for six months, and $74 for an annual plan. The longer-term figures describe a commitment billed in advance, not necessarily a monthly charge.
Before choosing a term, confirm the total due, the renewal date, cancellation and refund rules, and what happens if treatment is not appropriate or later changes. The introductory refund language should be read in the actual enrollment terms rather than generalized beyond its stated conditions.
Checked with: Ro: current program pricing
The medicine adds another line
Medication pricing depends on the product, strength, cash-pay offer, insurance situation, and any selected multi-month arrangement. Ro’s public pages advertise both Wegovy pills and injections, with product-specific prices and conditions. A starting medication figure should not be assumed to apply throughout treatment.
Our NovoCare review records manufacturer program terms that help explain the medication side of the bill. Our cost guide keeps the membership and prescription separate. Neither page can establish your final out-of-pocket amount or guarantee that a particular insurance benefit will apply.
Checked with: Ro: current program pricing · NovoCare: Wegovy pharmacy offer
Do not choose the product from the price list
Wegovy tablets and injections have different administration instructions and some different labeled uses. The prescriber should decide which product, if any, fits the assessment. The lowest listed price is not a reason to choose a strength, alter a schedule, or switch formulations on your own.
Read the pill and injection comparison for questions about the practical routine. Ro’s broader GLP-1 catalog also includes medicines with different active ingredients, so a general program description should not be interpreted as semaglutide-specific instructions. Ask for the exact name on the proposed prescription.
Checked with: Wegovy: current prescribing information · Ro: weight-management program
Ask how ongoing care works
Clarify who receives messages, what response time to expect, when a separate appointment is needed, and how a refill is reviewed. Confirm that the clinician is authorized to treat you in your physical location and that the pharmacy can serve it. If you travel or move, ask what changes in the care arrangement.
The safety guide can help you prepare questions about symptoms and other medicines. Routine messaging should not be treated as an emergency service. This review did not measure response times or verify appointment access across every state, so those details remain direct-confirmation questions.
Checked with: HHS: telehealth location and licensing · Ro: weight-management program · Wegovy: current prescribing information
Where Ro fits in the comparison
Ro offers a clinical program model with separate prescription spending. NovoCare is a manufacturer access route, while the CoreAge offer reviewed here concerns compounded semaglutide and brings additional approval and compounding questions. These differences are more useful than an invented star score.
Use the cost planner with a written quote, then compare the support and product details. Our shortlist clearly labels CoreAge’s paid first placement. We have not established that any listed service produces better medical outcomes, and the commercial order should not be mistaken for such a finding.
Checked with: Ro: current program pricing · NovoCare: Wegovy pharmacy offer · FDA: concerns about unapproved GLP-1 products
Where we checked the facts
- Ro: current program pricing
Membership and medication are separate charges. $39 introductory membership; $149 ongoing monthly or lower prepaid equivalents, subject to terms.
- Ro: weight-management program
Provider description of assessment and ongoing care, not independent patient-outcome evidence.
- NIDDK: prescription weight-management medicines
Background about clinical assessment and ongoing care; current product label controls newer formulation details.
- NovoCare: Wegovy pharmacy offer
Manufacturer access and pricing terms checked September 23, 2026. Formulation, strength, eligibility and offer period affect cost.
- Wegovy: current prescribing information
June 2026 label includes oral and injectable formulations with product-specific uses and instructions. Do not apply one formulation’s directions to another.
- HHS: telehealth location and licensing
Clinician authorization and physical patient location must be verified for the actual service.
- FDA: concerns about unapproved GLP-1 products
Current concerns include unapproved products, salt forms and adverse events. Compounding is not equivalent to generic approval.
